AROMICS is a development-stage biotechnology company focused on development of novel small molecules targeting RNA for treatment of cancer. NAX035 is the first lead advancing into clinics. As first indication, we have selected malignant mesothelioma, a rare and incurable cancer related to asbestos exposure.